STOCK TITAN
  1. Home
  2. News
  3. IMMX

Immix Biopharma, Inc. - IMMX STOCK NEWS

Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.

Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company leading the way in the development of innovative cell therapies for autoimmune diseases and hematologic malignancies. The company's flagship product, NXC-201, is a next-generation CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis and multiple myeloma. NXC-201 stands out due to its potential to be the world’s first 'Single-Day CRS' CAR-T, offering rapid treatment and the prospect of quick patient recovery.

Immix Biopharma leverages its proprietary TME Normalization Technology to develop Tissue-Specific Therapeutics (TSTx) that precisely target cancerous tissues while minimizing systemic side effects. Their leading projects include the NEXICART-1 and NEXICART-2 clinical trials, which are currently testing the efficacy and safety of NXC-201 in patients with relapsed/refractory conditions.

In recent developments, Immix Biopharma has received multiple Orphan Drug Designations (ODD) from both the FDA and the European Medicines Agency (EMA) for NXC-201 in treating AL Amyloidosis and multiple myeloma. This designation provides significant regulatory and financial incentives, highlighting the therapy's potential impact on these challenging diseases.

Immix Biopharma's IMX-110 is another key product in its pipeline, aimed at treating soft tissue sarcoma. Currently under evaluation in Phase 1b/2a trials, IMX-110 has already been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, underscoring its potential for treating rare cancers.

The company has made significant strides over the past year, including receiving FDA investigational new drug clearance for NXC-201, advancing ongoing clinical trials, and forming strategic partnerships with leading research institutions such as Memorial Sloan Kettering Cancer Center. Their commitment to pioneering cell therapies is further evidenced by their recent awareness campaign, Be Proactive in AL™, aimed at improving the diagnosis and treatment of AL Amyloidosis.

With a robust clinical dataset and strong regulatory support, Immix Biopharma is well-positioned to bring transformative therapies to market, addressing unmet medical needs in autoimmune diseases and cancer. For more information, please visit www.immixbio.com.

News

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Rhea-AI Summary
Immix Biopharma, Inc. has announced the pricing of an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share, with expected gross proceeds of approximately $15 million. The company intends to use the net proceeds for NXC-201 clinical trials, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
offering
-
News

Immix Biopharma Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) announced an underwritten public offering of its common stock to fund NXC-201 clinical trials, working capital, and general corporate purposes. The offering is subject to market conditions, with the company intending to use the net proceeds for various purposes. Titan Partners Group, LLC is acting as the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.89%
Tags
offering
-
News

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Rhea-AI Summary
Immix Biopharma, Inc. announced FDA labeling change notifications for approved CAR-T products, focusing on the potential of their CAR-T candidates to address the unmet medical need in relapsed/refractory AL Amyloidosis. The company highlighted the favorable tolerability profile and lack of neurotoxicity in their ongoing Phase 1b/2 clinical trial, as well as the absence of observed secondary T-cell malignancies. The Chief Executive Officer and Chief Financial Officer expressed confidence in the potential of NXC-201 to treat AL Amyloidosis and other autoimmune indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
News

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) announces Dr. Sanchorawala joining Nexcella Scientific Advisory Board. Dr. Sanchorawala co-authored a study leading to daratumumab becoming a first-line standard of care for AL Amyloidosis. The company aims to advance NXC-201, a promising CAR-T therapy for relapsed/refractory AL Amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
management
-
News

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Rhea-AI Summary
Immix Biopharma, Inc. (IMBX) announces Dr. Marko Radic joining Nexcella Scientific Advisory Board. Dr. Radic is a renowned expert in autoimmune CAR-T cell therapy and antibody-mediated disorders, bringing valuable experience to the company's subsidiary. His belief in the potential of NXC-201 for treating autoimmune diseases is a positive sign for the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
management
-
News

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) announced 100% overall response rate and 70% complete response rate in standard of care relapsed/refractory AL Amyloidosis patients with updated Phase 1/2 data. The best responder duration of response was 23.7 months, and the U.S. observed prevalence of relapsed/refractory AL Amyloidosis is growing 12% per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
News

Building Tranquility: The Home Depot Foundation Joins Forces To Address PTSD Struggles for Army Veteran

Rhea-AI Summary
Immix Biopharma, Inc. (Nasdaq:IMMX) has received FDA clearance for the Investigational New Drug (IND) application for BCMA CAR-T NXC-201, allowing the expansion of studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. The favorable tolerability of NXC-201 also enables potential expansion into autoimmune indications. 72 patients have been dosed with NXC-201 ex-U.S., showing promising overall response rates in both AL Amyloidosis and multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
none
-
News

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

Rhea-AI Summary
Immix Biopharma, Inc. (Nasdaq: IMMX) will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit on December 5, 2023. The company, a clinical-stage biopharmaceutical firm, focuses on personalized therapies for oncology and immunology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) will host a virtual KOL event on November 29, 2023, to discuss its BCMA-Targeted CAR-T cell therapy candidate NXC-201, in development for relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma with planned expansion into autoimmune indications. NXC-201 has shown promising Phase 1/2a data in ALA and R/R MM, with IND clearance to expand dosing into the U.S. and presentations at the American Society for Hematology 65th Annual Meeting. The therapy has also been awarded Orphan Drug Designation by the FDA in both AL Amyloidosis and multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
conferences
News

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) receives FDA clearance for IND application of BCMA CAR-T NXC-201, expanding studies to U.S. sites for relapsed/refractory AL Amyloidosis. Favorable tolerability allows potential expansion into autoimmune indications. 72 patients previously dosed with NXC-201 ex-U.S. have shown promising overall response rates in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
clinical trial fda approval

FAQ

What is the current stock price of Immix Biopharma (IMMX)?

The current stock price of Immix Biopharma (IMMX) is $2.17 as of December 20, 2024.

What is the market cap of Immix Biopharma (IMMX)?

The market cap of Immix Biopharma (IMMX) is approximately 61.1M.

What is Immix Biopharma, Inc.?

Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing novel cell therapies for autoimmune diseases and hematologic malignancies.

What are the main products of Immix Biopharma?

The main products include NXC-201, a next-generation CAR-T cell therapy for AL Amyloidosis and multiple myeloma, and IMX-110, a treatment for soft tissue sarcoma.

What is NXC-201?

NXC-201 is a CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis and multiple myeloma, potentially offering the first 'Single-Day CRS' treatment.

What is the significance of the Orphan Drug Designation?

Orphan Drug Designation provides regulatory and financial incentives for developing treatments for rare diseases, highlighting the potential impact of therapies like NXC-201.

What recent achievements has Immix Biopharma made?

Recent achievements include FDA investigational new drug clearance for NXC-201, multiple ODD awards, and advancements in clinical trials and strategic partnerships.

What is the Be Proactive in AL™ campaign?

The Be Proactive in AL™ campaign aims to increase awareness and early diagnosis of AL Amyloidosis, and educate patients about available treatment options.

What is IMX-110?

IMX-110 is a tissue-specific therapeutic being evaluated in Phase 1b/2a trials for treating relapsed/refractory soft tissue sarcoma, with FDA Orphan Drug and Rare Pediatric Disease Designations.

Where can I find more information about Immix Biopharma?

You can find more information on their official website at www.immixbio.com.

What are the key features of NXC-201?

Key features of NXC-201 include its potential for 'Single-Day CRS' treatment, rapid patient recovery, and effectiveness in treating AL Amyloidosis and multiple myeloma.

Who are the key partners of Immix Biopharma?

Key partners include leading research institutions like Memorial Sloan Kettering Cancer Center, contributing to the advancement of clinical trials and research.

Stock IMMX logo
Immix Biopharma, Inc.

Nasdaq:IMMX

IMMX Rankings

#4747 Ranked by Market Cap
N/A Ranked by Dividends

IMMX Stock Data

61.07M
15.65M
40.1%
17.64%
1.58%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ANGELES